Guillain-Barré syndrome

Seminars in Neurology

Volumn 32, Issue 3, 2012, Pages 179-186

  Arcila Londono, Ximena ^a   Lewis, Richarda ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute inflammatory demyelinating polyradiculoneuropathy; acute motor and sensory axonal neuropathy; acute motor axonal neuropathy; Fisher syndrome; Guillain Barr syndrome

Indexed keywords

4 AMINOPYRIDINE; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; ERYTHROMYCIN; FC RECEPTOR; FLECAINIDE; GABAPENTIN; GANGLIOSIDE; GANGLIOSIDE GQ 1B ANTIBODY; HEPARIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; MEXILETINE; MIROCOCEPT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELIN PROTEIN; NAFAMSTAT MESILATE; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT EV576; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ACUTE MOTOR AND SENSORY AXONAL NEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; ACUTE PANDYSAUTONOMIA; ADD ON THERAPY; ANALGESIA; ANTIBODY TITER; ARTICLE; ARTIFICIAL VENTILATION; AUSCULTATION; BLADDER CATHETERIZATION; BLADDER DYSFUNCTION; CAMPYLOBACTER JEJUNI; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC PAIN; COMPRESSION STOCKING; CYTOMEGALOVIRUS; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DYSARTHRIA; DYSAUTONOMIA; ELECTRODIAGNOSIS; EPIDEMIOLOGY; EPSTEIN BARR VIRUS; EVOKED SOMATOSENSORY RESPONSE; EXERCISE; FATIGUE; FORCED VITAL CAPACITY; GUILLAIN BARRE SYNDROME; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; LIMB WEAKNESS; LUNG FUNCTION TEST; MORTALITY; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE TRAINING; MYCOPLASMA PNEUMONIAE; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NEUROGENIC BOWEL; NEUROPATHY; NONHUMAN; NOSE FEEDING; OPHTHALMOPLEGIA; OROPHARYNGEAL WEAKNESS; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PHAGOCYTOSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PYRAMIDAL TRACT; REHABILITATION; SPINAL ROOT; TRACHEOSTOMY; TREATMENT DURATION; TREATMENT OUTCOME; WEAKNESS;

ELECTRODIAGNOSIS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY;

EID: 84868244947     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1329196     Document Type: Article

References (71)

1. Haymaker W. E., Kernohan J. W. The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore): 1949; 28 1 59 141
2. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med: 1956; 255 2 57 65
3. Hughes R. A., Cornblath D. R. Guillain-Barré syndrome. Lancet: 2005; 366 9497 1653 1666
4. McGrogan A., Madle G. C., Seaman H. E., de Vries C. S. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology: 2009; 32 2 150 163
5. Rocha M. S., Brucki S. M., Carvalho A. A., Lima U. W. Epidemiologic features of Guillain-Barré syndrome in São Paulo, Brazil. Arq Neuropsiquiatr: 2004; 62 1 33 37
6. van Koningsveld R., Rico R., Gerstenbluth I., et al. Gastroenteritis- associated Guillain-Barré syndrome on the Caribbean island Curaçao. Neurology: 2001; 56 11 1467 1472
7. Hadden R. DM, Cornblath D. R., Hughes R. AC., et al. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol: 1998; 44 5 780 788
8. McKhann G. M., Cornblath D. R., Ho T. W., et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet: 1991; 338 8767 593 597
9. Kannan M. A., Ch R. K., Jabeen S. A., Mridula K. R., Rao P., Borgohain R. Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barré syndrome. Neurol India: 2011; 59 5 727 732
10. Shafqat S., Khealani B. A., Awan F., Abedin S. E. Guillain-Barré syndrome in Pakistan: similarity of demyelinating and axonal variants. Eur J Neurol: 2006; 13 6 662 665
11. Ropper A. H. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol: 1986; 43 11 1150 1152
12. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry: 1998; 65 2 218 224
13. Lyu R. K., Tang L. M., Cheng S. Y., Hsu W. C., Chen S. T. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry: 1997; 63 4 494 500
14. Yuan C. L., Wang Y. J., Tsai C. P. Miller Fisher syndrome: a hospital-based retrospective study. Eur Neurol: 2000; 44 2 79 85
15. McGrogan A., Madle G. C., Seaman H. E., de Vries C. S. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology: 2009; 32 2 150 163
16. Hadden R. DM, Karch H., Hartung H-P., et al. Plasma Exchange/ Sandoglobulin Guillain-Barré Syndrome Trial Group Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology: 2001; 56 6 758 765
17. Lasky T., Terracciano G. J., Magder L., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med: 1998; 339 25 1797 1802
18. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol: 2009; 169 3 382 388
19. Asbury A. K., Cornblath D. R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol: 1990; 27 Suppl S21 S24
20. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology: 1991; 41 617 618
21. Ruts L., van Koningsveld R., van Doorn P. A. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology: 2005; 65 1 138 140
22. Albers J. W., Donofrio P. D., McGonagle T. K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 1985; 8 6 528 539
23. Brown W. F., Feasby T. E. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain: 1984; 107 Pt 1 219 239
24. Brown W. F., Snow R. Patterns and severity of conduction abnormalities in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry: 1991; 54 9 768 774
25. Bromberg M. B. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Muscle Nerve: 2011; 43 6 780 794
26. Prineas J. W. Pathology of the Guillain-Barré syndrome. Ann Neurol: 1981; 9 Suppl 6 19
27. Hafer-Macko C. E., Sheikh K. A., Li C. Y., et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996b; 39 5 625 635
28. Kaida K., Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol: 2010; 223 1-2 5 12
29. Winer J. B. Guillain-Barré syndrome: clinical variants and their pathogenesis. J Neuroimmunol: 2011; 231 1-2 70 72
30. Hardy T. A., Blum S., McCombe P. A., Reddel S. W. Guillain-barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep: 2011; 11 3 197 204
31. Hardy T. A., Blum S., McCombe P. A., Reddel S. W. Guillain-Barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep: 2011; 11 3 197 204
32. Griffin J. W., Li C. Y., Ho T. W., et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol: 1996; 39 1 17 28
33. Feasby T. E., Gilbert J. J., Brown W. F., et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain: 1986; 109 Pt 6 1115 1126
34. Griffin J. W., Li C. Y., Ho T. W., et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol: 1996; 39 1 17 28
35. Takigawa T., Yasuda H., Kikkawa R., Shigeta Y., Saida T., Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol: 1995; 37 4 436 442
36. Fross R. D., Daube J. R., Fukutake T., Yuki N., Hattori T. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology: 1987; 37 9 1493 1498
37. Fross R. D., Daube J. R. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology: 1987; 37 1493 1498
38. Ogawara K., Kuwabara S., Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve: 2002; 26 6 845 849
39. Yuki N., Taki T., Takahashi M., et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol: 1994; 36 5 791 793
40. Chaudhry F., Gee K. E., Vaphiades M. S., Biller J., Jay W. GQ1b antibody testing in Guillain-Barre syndrome and variants. Semin Ophthalmol: 2006; 21 4 223 227
41. Phillips M. S., Stewart S., Anderson J. R. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry: 1984; 47 5 492 495
42. Barontini F., Di Lollo S., Maurri S., Lambruschini P. Localization of the pathological process in Miller Fisher syndrome. Ital J Neurol Sci: 1992; 13 3 221 225
43. Buchwald B., Bufler J., Carpo M., et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology: 2001; 56 1 67 74
44. Bullens R. W., Halstead S. K., O'Hanlon G. M., et al. Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve: 2005; 31 6 751 760
45. Nagashima T., Koga M., Odaka M., Hirata K., Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol: 2007; 64 10 1519 1523
46. Kashihara K., Shiro Y., Koga M., Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry: 1998; 65 5 799
47. Koga M., Yuki N., Ariga T., Morimatsu M., Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol: 1998; 86 1 74 79
48. Arai M., Susuki K., Koga M. Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without Anti-GT1a IgG antibody. Muscle Nerve: 2003; 28 2 246 250
49. Notturno F., Caporale C. M., Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve: 2008; 37 2 265 268
50. Koike H., Atsuta N., Adachi H., et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain: 2010; 133 10 2881 2896
51. Fagius J., Westerberg C. E., Olsson Y. Acute pandysautonomia and severe sensory deficit with poor recovery. A clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry: 1983; 46 8 725 733
52. Struhal W., Hödl S., Mazhar S., Ransmayr G. Acute pandysautonomiarestitutio ad integrum by high prednisolone therapy. Wien Klin Wochenschr: 2011; 123 15-16 508 511
53. Hughes R. A., Wijdicks E. F., Benson E., et al. Multidisciplinary Consensus Group Supportive care for patients with Guillain-Barré syndrome. Arch Neurol: 2005; 62 8 1194 1198
54. Walgaard C., Lingsma H. F., Ruts L., et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol: 2010; 67 6 781 787
55. The Guillain-Barré Syndrome Study Group Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology: 1985; 35 8 1096 1104
56. Raphaël J. C., Chevret S., Hughes R. A., Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev: 2002; 2 2 CD001798
57. Walgaard C., Jacobs B. C., van Doorn P. A. Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs: 2011; 16 1 105 120
58. van der Meché F. G., Schmitz P. I. Dutch Guillain-Barré Study Group A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med: 1992; 326 17 1123 1129
59. Hughes R. A., Raphaël J. C., Swan A. V., van Doorn P. A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev: 2001; 2 2 CD002063
60. Dalakas M. C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology: 2002; 59 12 06 S13 S21
61. Kuitwaard K., de Gelder J., Tio-Gillen A. P., et al. Pharmokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol: 2009; 66 597 603
62. Kuitwaard K., de Gelder J., Tio-Gillen A. P., et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol: 2009; 66 5 597 603
63. Farcas P., Avnun L., Frisher S., Herishanu Y. O., Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet: 1997; 350 9093 1747
64. van Koningsveld R., Steyerberg E. W., Hughes R. A., Swan A. V., van Doorn P. A., Jacobs B. C. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol: 2007; 6 7 589 594
65. Halstead S. K., Zitman F. M., Humphreys P. D., et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain: 2008; 131 1197 1208
66. Pritchard J., Gray I. A., Idrissova Z. R., et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology: 2003; 61 9 1282 1284
67. Garssen M. P., van Koningsveld R., van Doorn P. A., et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry: 2007; 78 9 1012 1013. Erratum in: J Neurol Neurosurg Psychiatry 2007 Dec;78(12):1416
68. Bechtold D. A., Yue X., Evans R. M., Davies M., Gregson N. A., Smith K. J. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain: 2005; 128 Pt 1 18 28
69. Bensa S., Hadden R. D., Hahn A., Hughes R. A., Willison H. J. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol: 2000; 7 4 423 426
70. Bever C. T. Jr, Young D., Anderson P. A., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology: 1994; 44 6 1054 1059
71. Kaida K., Ariga T., Yu R. K. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disordersa review. Glycobiology: 2009; 19 7 676 692